We are live on ! Find out more
TERN

Terns Pharmaceuticals
TERN

Delisted

TERN was delisted on the 4th of May, 2026.

Back to rankings

37 hedge funds and large institutions have $117M invested in Terns Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 16 increasing their positions, 6 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 6

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

9% more funds holding

Funds holding: 34 → 37 (+3)

0.88% less ownership

Funds ownership: 66.55% → 65.67% (-0.88%)

33% less capital invested

Capital invested by funds: $174M → $117M (-$57.6M)

Holders
37
Holders Change
+3
Holders Change %
+8.82%
% of All Funds
0.57%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
16
Reduced
6
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Antara Capital
New York
+$1.46M
2
BlackRock
BlackRock
New York
+$1.19M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$980K
4
SCM
Suvretta Capital Management
New York
+$942K
5
BCM
Bridgeway Capital Management
Texas
+$795K

Top Sellers

Rank Fund Capital Flow
1
MICM
Matthews International Capital Management
California
-$9.12M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.1M
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$269K
4
STB
S&T Bank
Pennsylvania
-$104K
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$103K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$26.8M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$19.8M -$1.1M -132,177 -5%
VC
3
Vivo Capital
California
$18.9M – – –
DM
4
Deerfield Management
New York
$16.6M – – –
SCM
5
Suvretta Capital Management
New York
$8.76M +$942K +113,064 +10%
AC
6
Antara Capital
New York
$6.71M +$1.46M +175,000 +23%
BlackRock
7
BlackRock
New York
$5.27M +$1.19M +142,979 +24%
Vanguard Group
8
Vanguard Group
Pennsylvania
$3.95M +$980K +117,655 +27%
SB
9
Samsara BioCapital
California
$2.04M – – –
Geode Capital Management
10
Geode Capital Management
Massachusetts
$1.28M -$103K -12,401 -6%
State Street
11
State Street
Massachusetts
$1.15M +$97.3K +11,679 +8%
Northern Trust
12
Northern Trust
Illinois
$792K -$40.6K -4,880 -4%
BCM
13
Bridgeway Capital Management
Texas
$675K +$795K +95,500 New
Morgan Stanley
14
Morgan Stanley
New York
$632K +$528K +63,412 +243%
CCM
15
CAAS Capital Management
New York
$607K – – –
CAC
16
Cowen and Company
New York
$601K – – –
Jacobs Levy Equity Management
17
Jacobs Levy Equity Management
New Jersey
$390K -$269K -32,312 -37%
Millennium Management
18
Millennium Management
New York
$377K +$444K +53,281 New
Bank of New York Mellon
19
Bank of New York Mellon
New York
$253K +$68.2K +8,187 +30%
Charles Schwab
20
Charles Schwab
California
$204K -$23.3K -2,797 -9%
MAM
21
Marquette Asset Management
Minnesota
$117K +$138K +16,619 New
Goldman Sachs
22
Goldman Sachs
New York
$108K +$127K +15,208 New
PPA
23
Parametric Portfolio Associates
Washington
$87K +$103K +12,317 New
N
24
Nuveen
North Carolina
$83K – – –
Deutsche Bank
25
Deutsche Bank
Germany
$63K +$3.66K +440 +5%
1
2

TERN Hedge Fund Activity: Q4 2021 in Review

37 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Terns Pharmaceuticals (TERN) for Q4 2021, worth a combined $117M — down 33% from $174M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new TERN positions and 3 closed out — a net gain of 3 holders — while 16 added to existing stakes and 6 trimmed.

The largest buyer was Antara Capital, adding an estimated $1.46M. The largest seller was Matthews International Capital Management, exiting entirely with an estimated $9.12M sold.

  • 37 institutional investors held Terns Pharmaceuticals (TERN) as of Q4 2021, up from 34 in Q3 2021.
  • Funds reported $117M of Terns Pharmaceuticals stock for Q4 2021, down 33% quarter-over-quarter.
  • 6 funds opened new Terns Pharmaceuticals positions in Q4 2021 and 3 closed out, a net change of +3 holders.
  • The largest Terns Pharmaceuticals buyer in Q4 2021 was Antara Capital, an estimated $1.46M added.
  • The largest Terns Pharmaceuticals seller in Q4 2021 was Matthews International Capital Management, an estimated $9.12M sold.

Based on aggregated 13F filings for Q4 2021.